Biologics CDMO Secondary Packaging Market Size and Share Analysis by Type (Boxes, Cartons), Primary Package Type (Ampoules, Blister Packs, Bottles, Cartridges, Syringes and Vials, Prefilled Syringes) - Global Industry Revenue Estimation and Demand Forecast to 2030

Market Overview

The global biologics CDMO secondary packaging market was valued at $1,711.7 million in 2021, which is expected to reach $3,622.6 million by 2030, growing at a CAGR of 8.7% during the forecast period. This growth can be mainly attributed to the increasing production of drugs, the growing pharmaceutical industry, and the rising prevalence of various diseases, including chronic diseases, infectious diseases, and genetic disorders.

Several companies are increasingly investing in the expansion of their business in different geographies, for increasing their penetration. For instance, in April 2022, Catalent Inc. announced a multi-year $350-million investment in its facility in Bloomington, Indiana, to expand its drug manufacturing capabilities and biologics drug substance portfolio. Moreover, in October 2021, Lonza Group Ltd. announced its plan to expand its mammalian cell development services in Singapore. The expansion would establish an additional capacity for cell culture, purification, and analytical services for mammalian biologics.

The production of biological products has risen during the past few years, which strengthens the demand and production of associated secondary packing materials. Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. As per clinicaltrials.gov, around 0.3 million clinical trials were registered in 2019, and over thirty thousand studies were enumerated in the same year in the U.S. Additionally, in 2019, approximately 48 novel drugs were approved as per the data provided by the Center for Drug Evaluation and Research (CDER), the Food and Drug Administration (FDA).

Secondary packing plays an imperative role in the supply chain of drugs, as it encloses life-saving drugs and medicines and preserves their identity, quality, integrity, and stability. Moreover, these materials prevent product leakage and wear and tear, when subjected to normal handling.

Companies Involve in Partnerships with Biologics CDMOs Boost Market Revenue

Biopharmaceutical companies promise to launch several novel products, including therapies for diseases, to meet significant unmet medical needs. Also, more than 7,800 products in clinical development span a wide range of therapeutic areas, including cancer, cardiovascular, diabetes, neurology, and others, due to significant investments in R&D. Moreover, nearly 70% of clinical-phase projects have the potential to outperform first-in-class treatments, and the rapidly expanding pipeline includes products that may provide physicians with novel approaches to disease management.

Moreover, innovations and advancements in the biopharmaceutical sector provide incredible hope for patients across the globe, as the commercialization of products is complex and can be troubled with challenges. Emerging biopharma companies account for more than 65% of molecules in the R&D pipeline. Thus, many small and medium biopharma players looking for partnerships with bio-CDMOs to maximize their product success and navigate the risks of a dynamic and ever-changing market.

For instance, WuXi Biologics and BravoBio Co. Ltd. announced their collaboration for accelerating the development and commercial manufacturing of BravoBio’s vaccines for the treatment of infectious diseases, in January 2022. Through this, BravoBio would use WuXi Vaccines’ integrated platforms for GMP manufacturing of clinical supplies, conducting preclinical research, and global commercial supply of multiple innovative vaccine candidates of BravoBio.

Boxes Dominate Market

Boxes emerged as the largest type category in the biologics CDMO secondary packaging market, with around $1 billion revenue, in 2021, and they are also expected to retain their dominance during the forecast period. Boxes are engineered and designed explicitly for the transportation of biological products, including frozen and controlled ambient biologics. They also offer the perfect balance between payload and temperature control. Moreover, these are designed to meet the highest standards of biological drugs’ packing, and the exclusive custom-engineered solution accomplishes a high level of quality, while being sensitive to global environmental issues.

Blister Packs To Escalate Fastest Growth

Among the primary package types, blister packs accounted for the largest market share, around 40%, in 2021, and this category is also expected to record the highest CAGR during the forecast period. This is because they are the most significant type of packing containers for which the major proportion of the CDMOs provide secondary packaging services. Blister packaging is a viable solution for the sensitive nature of biologics, due to its versatility and transparency. Moreover, several manufacturers are gradually shifting toward monodose packing solutions; therefore, the sales of these packs are increasing at the highest pace.

Shift in Preference toward CDMOs Fuels Market Growth

Big biopharmaceutical companies are striving to de-risk R&D efforts and increase the speed to market their critical drugs, while simultaneously reducing their development and manufacturing costs. A rising number of specialty and biotech firms are turning to drug development and manufacturing service providers to avoid the high fixed costs of in-house development, production, and the expertise required to get their molecules through clinical development.

In addition, the high fixed costs associated with developing internal competencies limit the ability to scale up and down of companies, based on the nature and size of their pipeline and ever-changing requirements. CDMOs provide this agility and flexibility to biopharmaceutical companies to allow them to spend a large portion of their capital and profits on R&D, to create better drugs at lower costs. This way, the strategic usage of external CDMO partners grants companies a significant competitive advantage.

Moreover, biopharmaceutical players are consolidating their supplier base and preferring to work with CDMOs that provide services such as drug substance and drug product development, as well as manufacturing. To meet the market demand, CDMOs are expanding their capabilities across all stages of development and commercialization, in order to eliminate the need for technology transfer and serve customers end to end. Therefore, this fortifies the demand for secondary packaging solutions across the globe.

Explore more about this report - Request free sample

North America Is Principal Revenue Contributor

In 2021, North America accounted for the largest revenue share, over 40%, in the biologics CDMO secondary packaging market. This is attributed to the rising outsourcing of drug R&D and production activities by biopharma players. Many companies desire to team up with qualified packing providers that provide non-traditional packing solutions and have the essential abilities to make unique packing designs in a cost- and time-effective manner.

As per a survey, specifically for clinical and commercial-scale operations, more than half of the CDMOs currently have in-house secondary packing facilities, while the rest outsource these activities. Further, several recent developments in technologies, packaging designs, and materials have empowered service providers to provide several user-friendly pharmaceutical secondary packing solutions.

On the other hand, the APAC market is expected to witness the fastest growth during the forecast period. This growth can be mainly attributed to the surging prevalence of chronic diseases, the increasing focus of companies on contract manufacturing, and major players are showing a strong interest in facility expansions in the region.

Moreover, the region has witnessed extensive pharmaceutical contract development and manufacturing over the past several years. In recent times, the industry has experienced a distinct shift both in the nature and manner of contract manufacturing and how drug products are distributed. Traditionally, medicines that were manufactured in the region were also primarily intended for use in APAC countries. Therefore, due to the increasing demand for biologic CDMO services, the revenue generated through CDMO secondary packaging is rising.

In addition, the European market is projected to register moderate growth over the forecast period. This can be primarily due to the rising demand for biologic products, such as vaccines, which is driving the R&D expenditure of pharma companies.

Furthermore, the increasing demand for CDMO services for large-scale biologics production has propelled the demand for packaging products for vaccines, cell therapies, and other sensitive biological products. The packages are designed to withstand cryogenic temperatures, without hindering the quality of biological materials or their durability. Also, the percentage of biological drugs in the pharmaceutical pipeline continues to increase in the region.

Key Players in the Biologics CDMO Secondary Packaging Market Are:

• Catalent Inc.
• Rentschler Biopharma SE
• Emergent BioSolutions Inc.
• WuXi Biologics (Cayman) Inc.
• Samsung Biologics Co. Ltd.
• Lonza Group Ltd.
• Pfizer Inc.
• FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
• Thermo Fisher Scientific Inc.
• Eurofins Scientific

Market Size Breakdown by Segment

This report offers deep insights into the market, with size estimation for 2017 to 2030, the major drivers, restraints, trends and opportunities, and competitor analysis.

Based on Type

• Boxes
• Cartons

Based on Primary Package Type

• Ampoules
• Blister Packs
• Bottles
• Cartridges
• Syringes and Vials
• Prefilled Syringes

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • U.A.E.